https://www.selleckchem.com/products/2-nbdg.html
14% vs 0.26%; P= .01), renal failure (0.87% vs 0.09%; P= .007), reoperations (1.84% vs 0.26%; P .001), and new-onset atrial fibrillation (34.21% vs 13.04%; P .001). Survival was similar between the matched groups at 30 days (99.56% vs 99.21%), 1 year (97.73% vs 97.46%), and 5 years (91.15% vs 92.48%) (all P .05). Readmission rates were also comparable at all time intervals, and there were no differences in cardiac-related or heart failure-specific readmissions (all P .05). Risk-adjusted analyses confirmed these findin
Mi piace
Commento
Condividi
